

ERYTECH Pharma Voting Results by Resolution from Annual General Meeting Held on June 21, 2019

ERYTECH PHARMA

French *Société Anonyme*
With a share capital of Euros 1 794 003,50
Head Office: 60 Avenue Rockefeller
69008 LYON - FRANCE
479 560 013 RCS LYON

Number of shares composing the capital : 17 940 035 shares

Number of shares with voting right : 17 937 535 shares

Number total of voting rights : 19 526 589 voting rights

Legal *quorum* :

- For the extraordinary decisions, is 25% of the shares having the right to vote, as to know 4,484,384 shares;
- For the ordinary decisions, is 20% of the shares having the right to vote, as to know 3 587 507 shares.

| | Number of Shareholders | Number of shares | Number of voting rights |
|---------------------------------|------------------------|------------------|-------------------------|
| Present to the meeting | 17 | 16 656 | 26 958 |
| Proxies | 0 | 0 | 0 |
| Proxies to the President | 11 | 260 815 | 261 177 |
| Postal voting forms | 33 | 8 700 739 | 10 180 699 |
| Total | 61 | 8 978 210 | 10 468 834 |

The date of the General Shareholders' Meeting, the quorum was 50.052% representing 8 978 210 shares for 61 shareholders and 17,937,535 shares with voting rights.

Results by resolution :

I. Ordinary General Meeting

| Resolutions (n#) | Resolutions (subject) | Results | Voting Rights | | | | | | | |
|---------------------|---|---------|---------------|---------|---------------|--------|---------------|-------|---------------|----------|
| | | | Voted for | | Voted against | | Abstention | Total | | |
| | | | Voting rights | % | Voting rights | % | Voting rights | % | Voting rights | Off Vote |
| 1 | Approval of the financial statements for the year ended December 31, 2018 | Adopted | 10 468 743 | >99.99% | 100 | <0.01% | 0 | 0.00% | 10 468 834 | 0 |
| 2 | Approval of the consolidated financial statements for the year ended December 31, 2018 | Adopted | 10 468 743 | >99.99% | 100 | <0.01% | 0 | 0.00% | 10 468 834 | 0 |
| 3 | Allocation of the profit/(loss) for the year | Adopted | 10 468 743 | >99.99% | 100 | <0.01% | 0 | 0.00% | 10 468 834 | 0 |
| 4 | Statutory auditors' special report on the regulated agreements and commitments with related parties | Adopted | 10 446 584 | >99.99% | 100 | <0.01% | 0 | 0.00% | 10 446 684 | 23 483 |
| 5 | Approval of the commitments set out in article I. 225-38 of the French commercial code concerning changes to the compensation of Jérôme Bailly | Adopted | 10 397 412 | 99.32% | 71 422 | 0.68 % | 0 | 0.00% | 10 468 834 | 1 333 |
| 6 | Approval of the commitments described in article I.225-38 of the French commercial code concerning the change in the provision of tax-related services to GIL Beyen | Adopted | 10 465 403 | 99,98% | 1 885 | 0.02% | 0 | 0.00% | 10 467 288 | 1 546 |

| | | | | | | | | | | |
|----|--|---------|------------|---------|-----------|--------|---|-------|------------|--------|
| 7 | Approval of the elements of the compensation policy for executive corporate officers | Adopted | 7 631 420 | 73.06% | 2 814 491 | 26.94% | 0 | 0.00% | 10 445 911 | 24 256 |
| 8 | Approval of the elements of fixed, variable and exceptional compensation allocated to Gil Beyen for the year ended December 31, 2018 | Adopted | 7 652 799 | 73.11% | 2 814 489 | 26.89% | 0 | 0.00% | 10 467 288 | 1 546 |
| 9 | Appointment of Jean-Paul KRESS as Director | Adopted | 10 228 376 | 97.70% | 240 458 | 2.30% | 0 | 0.00% | 10 468 834 | 0 |
| 10 | Renewal of the term of office of Gil BEYEN as Director | Adopted | 10 468 682 | >99.99% | 152 | <0.01% | 0 | 0.00% | 10 468 834 | 0 |
| 11 | Renewal of the term of office of Luc DOCHEZ as Director | Adopted | 8 228 619 | 78.60% | 2 240 215 | 21.40% | 0 | 0.00% | 10 468 834 | 0 |
| 12 | Renewal of the term of office of Philippe ARCHINARD as Director | Adopted | 7 883 983 | 75.31% | 2 584 851 | 24.69% | 0 | 0.00% | 10 468 834 | 0 |
| 13 | Renewal of the term of office of GALENOS as Director | Adopted | 8 228 519 | 78.60% | 2 240 315 | 21.40% | 0 | 0.00% | 10 468 834 | 0 |
| 14 | Setting of attendance fees allocated to the Board of Directors | Adopted | 10 408 739 | 99.43% | 60 095 | 0.57% | 0 | 0.00% | 10 468 834 | 0 |
| 15 | Appointment of co-statutory-auditor | Adopted | 10 467 188 | >99.99% | 100 | <0.01% | 0 | 0.00% | 10 467 288 | 1 546 |

| | | | | | | | | | | |
|-----------|---|----------------|------------|---------|---------|--------|---|-------|------------|---|
| 16 | Appointment of an alternate joint statutory auditor | Adopted | 10 338 734 | 99.23% | 80 100 | 0.77% | 0 | 0.00% | 10 468 834 | 0 |
| 17 | Approval of the regulations of the share subscription and/or purchase options plan adopted by the board of directors on September 7, 2018 | Adopted | 10 214 452 | 97.57% | 254 382 | 2.43% | 0 | 0.00% | 10 468 834 | 0 |
| 18 | Authorization for the company to buy back its own shares | Adopted | 10 338 734 | 99.23% | 80 100 | 0.77% | 0 | 0.00% | 10 468 834 | 0 |
| 33 | Powers for carrying out formalities | Adopted | 10 468 534 | >99.99% | 300 | <0.01% | 0 | 0.00% | 10 468 834 | 0 |

II. Assemblée Générale ExtraOrdinaire

| Resolutions (n°) | Resolutions (subject) | Results | Voting Rights | | | | | | | |
|---------------------|--|---------|---------------|--------|---------------|--------|---------------|-------|---------------|----------|
| | | | Voted for | | Voted against | | Abstention | | Total | |
| | | | Voting rights | % | Voting rights | % | Voting rights | % | Voting rights | Off Vote |
| 19 | Authorization for the board of directors to reduce the company's share capital by canceling treasury shares | Adopted | 10 318 952 | 98.57% | 149 882 | 1.43% | 0 | 0.00% | 10 468 834 | 0 |
| 20 | Delegation of authority to the board of directors to issue common shares of the company and securities convertible to common shares to be issued immediately or in the future by the company, with existing shareholders' preferential subscription rights maintained | Adopted | 7 884 586 | 75.31% | 2 584 248 | 24.69% | 0 | 0.00% | 10 468 834 | 0 |
| 21 | Delegation of authority to the board of directors to issue common shares of the company and securities convertible to common shares to be issued immediately or in the future by the company, with shareholders' preferential subscription rights waived in the context of a public offering | Adopted | 7 418 935 | 70.87% | 3 049 899 | 29.13% | 0 | 0.00% | 10 468 834 | 0 |

| | | | | | | | | | | |
|----|---|---------|-----------|--------|-----------|--------|---|-------|------------|---|
| 22 | Delegation of authority to the board of directors to issue common shares of the company and securities convertible to common shares to be issued by the company immediately or in the future, with preferential subscription rights waived, in connection with offerings within the provisions in section ii of article I.411-2 of the french monetary and financial code | Adopted | 7 419 075 | 70.87% | 3 049 759 | 29.13% | 0 | 0.00% | 10 468 834 | 0 |
| 23 | Authorization to the board of directors to set the price of any issue of common shares of the company or securities convertible to common shares to be issued by the company, with preferential subscription rights waived, at an amount not to exceed 10% of share capital per year in accordance with the conditions set out by the general shareholders' meeting | Adopted | 7 250 115 | 69.25% | 3 218 719 | 30.75% | 0 | 0.00% | 10 468 834 | 0 |
| 24 | Authorization for the board of directors, in the case of a capital increase with existing shareholders' preferential subscription rights maintained or waived, to increase the number of shares to be issued | Adopted | 7 250 065 | 69.25% | 3 218 769 | 30.75% | 0 | 0.00% | 10 468 834 | 0 |
| 25 | Delegation of authority to the board of directors, with shareholders' preferential subscription rights waived, to increase the company's share capital through an issue reserved for certain categories of investors | Adopted | 7 249 925 | 69.25% | 3 218 909 | 30.75% | 0 | 0.00% | 10 468 834 | 0 |
| 26 | Delegation of authority to the board of directors to issue common shares of the company and securities convertible to common shares to be | | 7 418 977 | 70.87% | 3 049 857 | 29.13% | 0 | 0.00% | 10 468 834 | 0 |

| | | | | | | | | | | |
|-----------|--|-----------------|-----------|--------|-----------|--------|---|-------|------------|---|
| | issued by the company in the event of a public exchange offer initiated by the company, with shareholders' preferential subscription rights waived | Adopted | | | | | | | | |
| 27 | Authorization to the board of directors to issue common shares or securities convertible to common shares to be issued, with shareholders' preferential subscription rights waived, in consideration of contributions in kind granted to the company and consisting of shares of stock or securities convertible to shares | Adopted | 7 375 109 | 70.45% | 3 093 725 | 29.65% | 0 | 0.00% | 10 468 834 | 0 |
| 28 | Delegation of authority to the board of directors to increase the capital by incorporating reserves, profits or premiums | Adopted | 7 444 789 | 71.11% | 3 024 045 | 28.89% | 0 | 0.00% | 10 468 834 | 0 |
| 29 | Delegation of authority to the board of directors to carry out capital increases reserved for employees participating in an Erytech pharma group savings plan, with shareholders' preferential subscription rights waived | Rejected | 4 308 160 | 41.15% | 6 160 674 | 58.85% | 0 | 0.00% | 10 468 834 | 0 |
| 30 | Authorization for the board of directors to award bonus shares, existing or to be issued, with existing shareholders' preferential subscription rights waived, to corporate officers or employees of the company or related companies | Adopted | 7 655 303 | 73.12% | 2 813 531 | 26.88% | 0 | 0.00% | 10 468 834 | 0 |
| 31 | Authorization for the board of directors to grant share subscription and/or share purchase options to corporate officers and employees of the company or companies in the Erytech pharma group, entailing the waiver by shareholders of their preferential | Adopted | 7 655 335 | 73.13% | 2 813 499 | 26.87% | 0 | 0.00% | 10 468 834 | 0 |



| | | | | | | | | | | |
|----|---|---------|-----------|--------|-----------|--------|---|-------|------------|---|
| | rights to subscribe for shares issued following the exercise of stock options | | | | | | | | | |
| 32 | Authorization for the board of directors to issue share subscription warrants, with existing shareholders' preferential subscription rights waived, to corporate officers or employees of the company or erytech pharma group companies | Adopted | 7 655 475 | 73.13% | 2 813 359 | 26.87% | 0 | 0.00% | 10 468 834 | 0 |

About ERYTECH: www.erytech.com

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs.

ERYTECH's primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company's lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell's altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is also developing erymethionase, which consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers.

ERYTECH produces product candidates at its GMP-approved manufacturing site in Lyon, France, and at the American Red Cross in Philadelphia, USA. A large-scale GMP manufacturing facility has recently opened for operations in Princeton, New Jersey, USA and will begin manufacturing later this year.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.



CONTACTS

ERYTECH
Eric Soyer
CFO & COO

+33 4 78 74 44 38
investors@erytech.com

NewCap
Mathilde Bohin / Louis-Victor Delouvrier
Investor relations
Nicolas Merigeau
Media relations

+33 1 44 71 98 52
erytech@newcap.eu

